Sign Out
Intravenous vancomycin crosses the placenta. In one small controlled study, infants whose mothers were treated with vancomycin in their second or third trimester of pregnancy had no sensory neural hearing loss or nephrotoxicity that was attributed to vancomycin therapy. Vancomycin concentration monitoring is essential to reduce risk of fetal toxicity. Vancomycin should only be used if the potential benefit outweighs the potential risk.
Parenteral vancomycin distributed into breast milk. Although available data regarding the use of vancomycin while breast-feeding are limited, problems in humans have been documented.
